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used (proxy for comorbidity). Given the skewed distribution of
expenditure variables, multiple model speciﬁcations including
ordinary least squares regression, generalized linear model
(GLM) with Poisson, gamma and negative binomial variance
functions were evaluated. RESULTS: The prevalence of current
asthma among children in 2004 was estimated at 9.09%, i.e.,
6.7 million persons (95% CI: 8.27% to 9.99%) in the U.S. A
majority of children with asthma were male (61.6%), white
(68.1%), and insured (95.2%) with mean age of 8.9  0.25
years and education of 2.4  0.17 years. Children with asthma
had 69% higher total expenditures than non-asthmatics after
controlling for covariates (RR: 1.69; p < 0.0001). The annual
adjusted mean incremental total expenditure associated with
asthma was $661.7 (SE: $159.3; p < 0.0001) per person. Medi-
cations accounted for the largest proportion of the total expen-
ditures estimated at $197.9 (SE: $28.8; p < 0.0001), followed
by physician ofﬁce visits at $162.3 (SE: $57.7; p = 0.005) and
inpatient visits at $105.0 (SE: $75.9; p = 0.0167). CONCLU-
SION: Given the prevalence of asthma in children and its
associated incremental expenditures, the annual direct medical
expenditure for treating asthma in children is estimated at
approximately $4.4 billion in 2005 USD.
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OBJECTIVE: Cigarette smoking is one of the leading avoidable
causes of death in the world. However, in many countries, such
as Brazil, medications used during pharmacological treatments
are not supported by private or public health systems. The
purpose of this study is to analyze and to compare the ﬁnancial
impact of the costs related to adult smokers beneﬁciaries of a
health plan and deﬁne the best strategies to stimulate smoking
cessation programs. METHODS: We analyzed smoking habits,
based on an epidemiologic investigation of 46,407 beneﬁciaries
of a private health plan in Brazil. Expenses with hospitalization
and use of medical services during a period of 12 months, of
beneﬁciaries who report a daily smoking habit were compared
with those of non-smokers. Simulated analysis were performed
with the estimate costs of treatments with anti nicotin drugs a
potential decrease of the costs of the heath plan was estimated.
RESULTS: Among the beneﬁciaries, 29.0% (n = 10,270) were
smokers and 61.8% of those were male. The majority (86.7%) of
the smokers informed to consume 20 cigarettes per day; 9.5%
consumed 20 to 40 cigarettes per day and the rest of the group
(3.8%) consumed more than this amount. 43.3% smoked for less
than 10 years; 25.0% from 10 to 20 years and 31.6% for more
than 20 years. The prevalence of chronic diseases was higher
among the smokers, compared to non-smokers, as well as
average per capita cost expenditures (29% more than the non-
smokers). CONCLUSION: Starting from reported efﬁciency of
the nicotine replacement therapies added to psychological
support, applied to the group of smokers of the health plan and
comparing the costs of this strategy with the effective costs of
those beneﬁciaries, evidences demonstrate the importance of
considering ﬁnancial support systems to smoking cessation
interventions, by the health plan.
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OBJECTIVES: Asthma treatment guidelines and recent cost-
effectiveness models have shifted away from lung function out-
comes and moved toward emphasizing control. We developed
and validated a ﬂexible and transparent adult asthma policy
model that represents disease progression though levels of
asthma control and projects lifetime mortality, morbidity, and
costs. METHODS: We estimated uncertainty and point estimates
of model inputs for non-death transition state probabilities and
health state speciﬁc utilities and health care resource utilization
based on a rigorous analyses of a 3-year, multicenter, observa-
tional study of 4756 patients with difﬁcult-to-treat or severe
asthma receiving standard-of-care. We used statistical regression
models to test and account for population heterogeneity. We
validated the model following the ISPOR Task Force recommen-
dations. Three hypothetical scenarios were compared to
standard-of-care that resulted in different target product proﬁle
and pricing bands: A) a 30% relative reduction in exacerbation
rates with a $2000 per annum treatment cost; B) A plus a
threefold increased risk of asthma related death for the sub-
optimally controlled; C) B plus an absolute improvement in
utility by 0.02 for each health state. RESULTS: Simulation
cohorts, stratiﬁed by age and severity, transitioned through three
mutually exclusive levels of control until reaching death. Nine
health states were modeled because one cycle of control history
was predictive of present cost and utility. Compared to standard-
of-care, the three hypothetical scenarios resulted in societal
perspective incremental cost-effectiveness ratios of $284,000 per
QALY gained (95% interval: $193,000, $463,000), $263,000/
QALY (95% interval: $179,000, $422,000), and $62,000/QALY
(95% interval: $52,000, $72,000) respectively. CONCLU-
SIONS: This policy model adds to past asthma models because
its structure and inputs were based on current clinical guidelines
and a large long-term patient-level registry. This versatile model
can forecast: lifelong burden of disease, value of current and
emerging interventions, and parameters that yield the highest
return from further study.
PRS46
HOW PROCESS INFLUENCES SCIENTIFIC EVIDENCE FOR
HEALTH CARE POLICYMAKERS,THE CASE OF ECONOMICS
AND MEDICAL DECISION-MAKING PROCESSES
Huttin CCH
ENDEPUSresearch,Inc and University Paul Cezanne, Cambridge, MA,
USA
OBJECTIVE: This paper contributes to the debate on how
process affects reliability of scientiﬁc evidence in health care. It
discusses the use of different types of study designs in medicine
and biology versus social sciences to raise scientiﬁc international
evidence. METHODS: A comparison of study designs used in
clinical research (RCT and bridges studies (e.g. Hsiao CF et als,
2007)) and in social sciences. Examples from clinical sciences are
on environmental medicine and bridging studies. Examples from
social sciences are presented on two characteristics of six Euro-
pean hypertensive patient surveys on cost of medicines (ENDEP-
Lux, 2000): exemption criteria and classiﬁcation of medicines for
reimbursement. RESULTS: The comparison of case studies
shows similar problems for both clinical and ﬁnancing study
designs: imbalance of sample sizes between new and original sites
for clinical bridges studies, and between national sampled
patients with different access to health beneﬁts for ﬁnancing
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studies; the comparison also shows common recent development
of bayesian decision models and choices of appropriate weight-
ing of prior information (e.g. use of mixture prior information
for judging similarity by the “positive treatment effect” in clinical
research or use of different weighting between individual and
population level for the ﬁnancing studies). Moreover, selection of
appropriate weighting in both types of studies face regulators
and ﬁnancing agencies that need to have conﬁdence in the trans-
ferability of their results between regions. CONCLUSIONS:
New developments of statistical analysis especially Bayesian
evaluation both in global clinical research and social sciences can
lead to a better integration of types of research designs. They can
improve scientiﬁc evidence for health care policy decision pro-
cesses. Context free research is not sufﬁcient to integrate the
effect of environmental modiﬁers (like in asthma) or variations in
social and political processes (e.g. variation in exemption criteria
especially during health reforms or systems in transition).
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OBJECTIVE: This study attempted to determine if select patient
and physician demographic variables are predictors of the pre-
scribing of asthma pharmacotherapy in the ambulatory patient
population of the United States, with particular emphasis on the
non-African American minority population. Recent research sug-
gests that these populations may be at-risk for receiving sub-
optimal asthma care due to cultural and/or linguistic barriers to
obtaining proper care, cultural beliefs about asthma treatment,
low socio-economic status and even genetic polymorphisms that
lead to poor responses to asthma medications. METHODS: This
study was a retrospective cross-sectional study that used data
from the National Ambulatory Medical Care Survey (NAMCS)
from 1998 through 2004. The weighted population sample size
of the study was 82,020,318 patients and there were 1,540
observations in this study (pre-weighted sample size). Speciﬁc
patient demographic variables, physician demographic variables
and asthma medications prescribed were extracted from the
dataset and analyzed. RESULTS: A major ﬁnding from this study
was the fact that non-African American minority populations
were receiving sub-optimal asthma pharmacotherapy. Non-
African American minorities (Asians, Native Americans, Paciﬁc
Islanders, Alaskan Natives and other minorities) were less likely
to be prescribed controller medications (OR = 0.405), combina-
tions of ICS and LABA agents (OR = 0.267) and more likely to
be prescribed SABA agents (OR = 1.769) when compared to the
overall population [all p < 0.05]. Additionally, our research also
indicates that these minority patients are generally younger, more
likely to see primary care physicians, and are also likely to have
insurance coverage (public & private). They are also more likely
to reside in an urban area and live in the Western United. States.
CONCLUSION: It appears that a more concerted effort needs
to be undertaken to study the factors that may explain the
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OBJECTIVE: To evaluate the impact of psoriasis (PsO) on the
presence of co-morbidities in the ﬁrst year after the diagnosis.
METHODS: A retrospective study of the PharMetrics database,
compiled from managed care plans throughout the United States,
from January 1, 2000 through December 31, 2006 was con-
ducted. Patients between the ages of 18 to 80 years, who had a
minimum of 12 months of continuous enrollment before and
after their index diagnosis with PsO, were included. The index
diagnosis date was derived from the ﬁrst claim for PsO during the
study period. The presence of co-morbidities was determined by
frequency counts and as a percentage of total claims generated
during the study period. RESULTS: The study cohort included
48,068 patients; 52.3% were females, and the mean age was
46.3 years. Multiple co-morbidities were identiﬁed in the years
prior to and subsequent to the diagnosis of PsO. The ﬁve most
frequently observed co-morbidities were: hypertensive disease
(increased from 24.45% to 26.65%), hyperlipidemia (from
15.72% to 18.06%), pure hypercholesterolemia, pure hyperglyc-
eridemia, and mixed hyperlipidemia (from 14.65% to 16.18%),
diabetes mellitus (from 8.36% to 9.57%), depressive disorder,
episodic mood disorder, and dysthemic disorder (from 6.88% to
7.12%). Additionally, the ﬁve highest percentage increases in
co-morbidities in the years prior to and subsequent to the diag-
nosis of PsO were: 1) Malignant neoplasm of uterus and cervix
uteri (60%, pre-n = 26, post-n = 38); 2) Malignant neoplasm of
trachea, bronchus and lung (57.1%, pre-n = 33, post-n = 54); 3)
Malignant neoplasm of ovary and other uterine adnexa (44.4%,
pre-n = 42, post-n = 63); 4) Psoriatic Arthropathy (44.0%, pre-
n = 1357, post-n = 1950); and 5) Atherosclerosis (33.3%, pre-
n = 142, post-n = 193). CONCLUSION: This study indicates
that co-morbidities increase signiﬁcantly in the year subsequent
to a diagnosis of PsO. The large increases noted in malignancies
may be due to the small numbers of cases observed.
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OBJECTIVE: Five biological treatments are registered for pso-
riasis, the tumor necrosis alpha (TNF-alpha) inhibitor adali-
mumab, etanercept and inﬂiximab and the T-cell modulator
alefacept, efalizumab. Our objectives were to analyse the efﬁcacy
of registered biological drugs in psoriasis and also to compare
their efﬁcacy on a pharmacological group level. METHODS:
Cochrane Highly Sensitive Search Strategy was used to identify
RCTs in MEDLINE. Inclusion criteria were: a) treatment of
psoriasis b) outcome data on the proportions of patients achiev-
ing at least 75% improvement in Psoriasis Area and Severity
Index (PASI) from baseline. The quality of selected studies was
measured using the Jadad-score. Data were entered into Review
Manager 4.2 software. The chosen summary statistic variable
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